Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands

You may also be interested in...



Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market

FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.

Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market

FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.

Deals Of The Week: Bristol/Ono, Bristol/Ambrx, Merck Serono/Peptimmune

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel